Toni Choueiri, MD· @DrChoueiri · X·· 1 day agoScore70
Body · original
Elegant presentation by @Uro_Oncologist reporting HRQoL from #Keynote-B15.
Perioperative EV-P was not associated with clinically meaningful detriment in general HRQoL or cystectomy-specific HRQoL !
#ESMO26 #Day2 @myESMO @OncoAlert
84 views · 4 likes · 3 reposts · 0 replies
Conference abstracts
4734Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgNCT04700124NCT04700124matched by - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.orgSource: Toni Choueiri, MD · x.com